You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 百濟神州(6160.HK)漲3% 凱洛斯®首項多發性骨髓瘤適應症在中國獲批
格隆匯 07-09 15:00
格隆匯7月9日丨百濟神州(6160.HK)午後漲幅擴大,現報193.5港元,漲2.98%,暫成交5733萬港元,最新市值2323億港元。百濟神州今日午間宣佈,國家藥品監督管理局(NMPA)已經附條件批准凱洛斯®(KYPROLIS®,注射用卡非佐米)與地塞米松聯合適用於治療復發或難治性(R/R)多發性骨髓瘤(MM)成人患者,患者既往至少接受過2種治療,包括蛋白酶體抑制劑和免疫調節劑。百濟神州通過與安進的戰略合作,獲得凱洛斯®在中國的授權。這是凱洛斯®在中國獲批的首項適應症。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account